vascular endothelial growth factor-A (VEGF-A) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Posts Tagged ‘vascular endothelial growth factor-A (VEGF-A)’

On its way for an IPO: mRNA platform Immune-Oncology, Moderna, is recruiting 100 new Life Scientists in Cambridge, MA

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Computational Biology/Systems and Bioinformatics, Diagnostic Immunology, Drug Delivery Platform Technology, Drug Development Process, Drug Discovery Chemistry, Genetics & Innovations in Treatment, Genome Biology, Genomic Testing: Methodology for Diagnosis, Human Immune System in Health and in Disease, Immuno-Oncology & Genomics, Immunodiagnostics, Immunotherapy, Infectious Disease Immunodiagnostics, mRNA platform in Drug DIscovery, RNA Biology, RNA Biology, Cancer and Therapeutics, tagged mRNA-based therapy, vascular endothelial growth factor-A (VEGF-A) on September 7, 2016| Leave a Comment »

On its way for an IPO: mRNA platform, Moderna, Immune Oncology is recruiting 100 new Life Scientists in Cambridge, MA

Curator: Aviva Lev-Ari, PhD, RN

Deals:

Moderna has now raised $1.9 billion from investors like AstraZeneca – 9% stack [AstraZeneca’s Pascal Soriot helped get that all started with a whopping $240 million upfront in its 2013 deal, which was tied to $180 million in milestones.], with another $230 million on the table from grants. In addition to the financing announcement this morning, Moderna is also unveiling a pact to develop a new Zika vaccine, with BARDA putting up $8 million to get the program started while offering an option on $117 million more to get through a successful development program.

Novel Strategy in Biotech:

in biotech. Instead of grabbing one or two new drugs and setting out to gather proof-of-concept data to help establish its scientific credibility, the company has harvested a huge windfall of cash and built a large organization before even entering the clinic. And it did that without turning to an IPO.

Pipeline include:

The deal with AstraZeneca covers new drugs for cardiovascular, metabolic and renal diseases as well as cancer.
partners filed a European application to start a Phase I study of AZD8601, an investigational mRNA-based therapy that encodes for vascular endothelial growth factor-A (VEGF-A)
Moderna CEO spelled out plans to get the first 6 new drugs in the clinic by the end of 2016.
The first human study was arranged for the infectious disease drug mRNA 1440, which began an early stage study in 2015.
Moderna built up a range of big preclinical partnerships.
CEO Bancel says the number of drugs in development has swelled to 11, with the first set of data slated to be released in 2017.
Moderna also plans to add about 10 drugs to the clinic by next summer,

SOURCES

UPDATED: Booming Moderna is raising $600M while ramping up manufacturing and clinical studies

by john carroll – August 29, 2016

http://endpts.com/booming-moderna-is-adding-600m-while-ramping-up-manufacturing-and-clinical-studies/

$1.9B in: Moderna blueprints $100M facility, plans to double the pipeline after a $474M megaround

by john carroll – September 7, 2016

http://endpts.com/moderna-blueprints-100m-facility-plans-to-double-the-pipeline-after-a-474m-megaround/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202016-09-07%20BioPharma%20Dive%20%5Bissue:7155%5D&utm_term=BioPharma%20Dive

Moderna Therapeutics Deal with Merck: Are Personalized Vaccines here?

Curator & Reporter: Stephen J. Williams, PhD – August 11, 2016

https://pharmaceuticalintelligence.com/2016/08/11/moderna-therapeutics-deal-with-merck-are-personalized-vaccines-here/

at #JPM16 – Moderna Therapeutics turns away an extra $200 million: with AstraZeneca (collaboration) & with Merck ($100 million investment)

Reporter: Aviva Lev-Ari, PhD, RN – January 13, 2016